Our humanized patient-derived xenograft (PDX) platform (HSC-PDX) combines the predictive power of HuPrime® PDX models with human hematopoietic stem cell (HSC) engraftment. HSC-PDX models provide the most human disease relevant in vivo platform for your human-specific immunotherapy evaluation.
Human peripheral blood mononucleated cell (PBMC)-humanized mouse models provide a simple alternative to full stem cell reconstitution. Our MiXeno™ models are developed by combining human immune cells and conventional, cell line derived xenografts, with the resulting models showing reconstitution of T, B, and NK cell populations.
PBMC-humanized models provide a more rapid and cost-effective approach compared to full immune cell reconstitution. MiXeno models are used to evaluate a range of immuno-oncology applications including BiTE®-like antibodies, checkpoint inhibitors, antibody-dependent cellular cytotoxicity (ADCC) effects, and NK modulating agents.
Models are currently available for a range of cancer types including breast, colorectal, and lung cancer, as well as lymphoma, and melanoma.
Tell us how more about your project!